Tumour-associated macrophages might represent a favourable prognostic indicator in patients with papillary renal cell carcinoma

Histopathology

Volumn 63, Issue 3, 2013, Pages 309-315

  Hutterer, Georg C ^a   Pichler, Martin ^a   Chromecki, Thomas F ^a   Strini, Karin A ^a   Klatte, Tobias ^b   Pummer, Karl ^a   Remzi, Mesut ^c   Mannweiler, Sebastian ^a   Zigeuner, Richard ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Landesklinikum Korneuburg ^*  (Austria)

Author keywords

Macrophages; Papillary renal cell carcinoma; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEPHRECTOMY; PAPILLARY CARCINOMA; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION;

MACROPHAGES; PAPILLARY RENAL CELL CARCINOMA; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MACROPHAGES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84882565272     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12163     Document Type: Article

References (30)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 2008; 34; 193-205.
2. Sun M, Thuret R, Abdollah F et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 2011; 59; 135-141.
3. Figlin RA. Renal cell carcinoma: management of advanced disease. J. Urol. 1999; 161; 381-386.
4. Atkins MB, Avigan DE, Bukowski RM et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin. Cancer Res. 2004; 10; 6277S-6281S.
5. Kusmartsev S. Enhanced 15-lipoxygenase activity and elevated eicosanoid production in kidney tumor microenvironment contribute to the inflammation and immune suppression. Oncoimmunology 2012; 1; 249-251.
6. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001; 193; 727-740.
7. Sica A, Larghi P, Mancino A et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008; 18; 349-355.
8. Weiss JM, Ridnour LA, Back T et al. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 2010; 207; 2455-2467.
9. Wang D, Dubois RN. Eicosanoids and cancer. Nat. Rev. Cancer 2010; 10; 181-193.
10. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 2007; 178; 1357-1362.
11. Watkins SK, Li B, Richardson KS et al. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur. J. Immunol. 2009; 39; 2126-2135.
12. Wigginton JM, Kuhns DB, Back TC, Brunda MJ, Wiltrout RH, Cox GW. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 1996; 56; 1131-1136.
13. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics. Tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004; Chapter 1; 27-29.
14. Leibovich BC, Lohse CM, Crispen PL et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol. 2010; 183; 1309-1315.
15. Maj M, Wagner L. Molecular approaches to classify adult renal epithelial neoplasms. Exp. Rev. Mol. Diagn. 2011; 11; 803-806.
16. Pichler M, Hutterer GC, Chromecki TF, Pummer K, Mannweiler S, Zigeuner R. Presence and extent of histological tumour necrosis is an adverse prognostic factor in papillary type 1 but not in papillary type 2 renal cell carcinoma. Histopathology 2013; 62; 219-228.
17. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edition; Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80; 1803-1804.
18. Sengupta S, Lohse CM, Leibovich BC et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005; 104; 511-520.
19. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod. Pathol. 1997; 10; 537-544.
20. Pignot G, Elie C, Conquy S et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007; 69; 230-235.
21. Ficarra V, Brunelli M, Cheng L et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur. Urol. 2010; 58; 655-668.
22. Zucchi A, Novara G, Costantini E et al. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma. BJU Int. 2012; 109; 1140-1146.
23. Usubütün A, Ayhan A, Uygur MC, Ozen H, Toklu C, Ruacan S. Prognostic factors in renal cell carcinoma. J. Exp. Clin. Cancer Res. 1998; 17; 77-81.
24. Hamada I, Kato M, Yamasaki T et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002; 22; 4281-4284.
25. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am. J. Surg. Pathol. 1997; 21; 621-635.
26. Onishi T, Ohishi Y, Goto H, Suzuki M, Miyazawa Y. Papillary renal cell carcinoma: clinicopathological characteristics and evaluation of prognosis in 42 patients. BJU Int. 1999; 83; 937-943.
27. Weiss JM, Back TC, Scarzello AJ et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc. Natl Acad. Sci. U.S.A. 2009; 106; 19455-19460.
28. Passalacqua R, Buzio C, Buti S et al. Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer. Cancer Immunol. Immunother. 2010; 59; 553-561.
29. Herrmann E, Brinkmann OA, Bode ME et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil. Eur. Urol. 2007; 51; 1625-1631.
30. Ronnen EA, Kondagunta GV, Ishill N et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006; 107; 2617-2621.